NCT07459634 2026-03-10
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Jazz Pharmaceuticals
Phase 2 Not yet recruiting
Jazz Pharmaceuticals
AbbVie
Indiana University
Sichuan University
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Guangzhou Institute of Respiratory Disease